The value of histological changes and immunohistochemical markers Ki67 and p53 in the assessment of ulcerative colitis related dysplasia

• Authors: Ovidiu Fratila , Tiberia Ilias , Dana Puscasiu
• Languages of publication: EN

Abstracts

EN

The risk of carcinoma increases in patients with a 10-year or longer duration of ulcerative colitis (UC). To search for a more objective parameter to assess epithelial dysplasia. The study comprised 25 cases of longstanding UC: 7 cases with regenerative atypia, 7 with low grade dysplasia, 7 with high grade dysplasia, and 4 cases indefinite for dysplasia. The colonic biopsies obtained during endoscopy were stained with H&E to identify the aforementioned categories. Seventy-five sections from biopsy specimens were stained immunohistochemically to detect differences in the frequency and pattern of nuclei positive for the proliferation marker Ki67 and p53. In high grade dysplasia, the distribution of Ki67 positive cells was diffuse throughout the full length of the crypt, whereas low grade dysplasia and epithelium indefinite for dysplasia, as well as regenerative epithelium, showed an expanded basal zone. None of the regenerative atypia cases showed strong intensity p53 staining compared to dysplasia cases. None of the high grade dysplasia cases showed restricted p53 staining to the lower two thirds of the crypt. All the cases of HGD showed extension of Ki67 and p53 staining above the basal two thirds of the crypt. Ki67 and p53 immunostained cell assessment combined with routine histological evaluation of colorectal mucosa can improve the diagnostic accuracy, as well as the assessment of malignant transformation risk.

Keywords

EN

Ulcerative colitis; Histopathology; immunohistochemistry; Chronic inflammation; Dysplasia; Carcinoma

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2010
• Volume: 5
• Issue: 4
• Pages: 417-425

Dates

published

1 - 8 - 2010

online

30 - 5 - 2010

Contributors

author

Ovidiu Fratila

• Faculty of Medicine and Pharmacy, University of Oradea, 1st of December Street, 410073, Oradea, Romania

author

Tiberia Ilias

• Oradea Clinical County Hospital, Republicii Street, 410167, Oradea, Romania

author

Dana Puscasiu

• Faculty of Medicine and Pharmacy, University of Oradea, 1st of December Street, 410073, Oradea, Romania

References

• [1] Seidelin J., Vainer B., Andresen L., Nielsen O., Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis, Virchows Arch., 2007, 451, 1031–1038 http://dx.doi.org/10.1007/s00428-007-0517-1[Crossref][WoS]
• [2] Shigehiko F., Daisuke K., Fujimori T., Limits of Diagnosis and Molecular Markers for Early Detection of Ulcerative Colitis-Associated Colorectal Neoplasia, JGA Supplement, 2008 - Reviews in Basic and Clinical Gastroenterology
• [3] Van der Woude C.J., Moshage H., Homan M., Kleibeuker J.H., Jansen P., van Dekken H., Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis, J. Clin. Pathol., 2005, 58, 811–814 http://dx.doi.org/10.1136/jcp.2004.017418[Crossref]
• [4] Wong N.A., Mayer N.J., MacKellm S., Gilmour H.M., Harrison D.J., Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia, Histopathology, 2000, 37(2), 108–114 http://dx.doi.org/10.1046/j.1365-2559.2000.00934.x[Crossref]
• [5] Ilyas M., Talbot I.C., p53 expression in ulcerative colitis: a longitudinal study, Gut, 1995, 37, 802–804 http://dx.doi.org/10.1136/gut.37.6.802[Crossref]
• [6] Harpaz N., Peck A.L., Yin J., et al., p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma, Human Pathology, 1994, 25(10), 1069–1074 http://dx.doi.org/10.1016/0046-8177(94)90067-1[Crossref]
• [7] Andersen S.N., Rognum T.O., Bakka A., Clausen O., Ki67: a useful marker for the evaluation of dysplasia in ulcerative colitis, J. Clin. Pathol., Molecular Pathology, 1998, 51, 327–332 http://dx.doi.org/10.1136/mp.51.6.327[Crossref]
• [8] Kubota Y., Petras R.E., Easly K.A., et al., Ki67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma, Cancer, 1992, 70, 2602–2609 http://dx.doi.org/10.1002/1097-0142(19921201)70:11<2602::AID-CNCR2820701106>3.0.CO;2-W[Crossref]
• [9] Suzuki H., Matsumoto K., Terabe M., Ki67 antibody labeling index in colorectal carcinoma, J. Clin. Gastroenterology, 1992, 15, 317–320
• [10] Kullmann F., Fadaie M., Gross V., et al., Expression of proliferating cell nuclear antigen (PCNA) and Ki67 in dysplasia in inflammatory bowel disease, European Journal Gastroenterology Hepatology, 1996, 8, 371–379
• [11] Deschner E.E., Winawer S.J., Katz S., et al., Proliferative defects in ulcerative colitis patients, Cancer Invest. 1983, 1, 41–47 http://dx.doi.org/10.3109/07357908309040931[Crossref]
• [12] Deschner E.E., Early proliferative changes in gastrointestinal neoplasia, American Journal Gastroenterology, 1982, 77, 207–211
• [13] Lipkin M., Phase 1 and phase 2 proliferative lesions of colonic epithelial cells in diseases leading to colonic cancer, Cancer, 1974, 34, 878–888 http://dx.doi.org/10.1002/1097-0142(197409)34:3+<878::AID-CNCR2820340715>3.0.CO;2-R[Crossref]
• [14] Alpers D.H., Philpott G., Grimme N.L., et al., Control of thymidine incorporation in mucosal explants from patients with chronic ulcerative colitis, Gastroenterology, 1980, 78, 470–478
• [15] Hall P.A., Lane D.P., p53 in tumour pathology: can we trust immunohistochemistry?, J. Pathol., 1994, 172, 1–4 http://dx.doi.org/10.1002/path.1711720103[Crossref]
• [16] Burmer G.C., Rabinovitch P.S., Haggitt R.C., et al., Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele, Gastroenterology, 1992, 103, 1602–1610
• [17] Chaubert P., Benhattar J., Saraga E., Costa J., K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis, American Journal Physiology, 1994, 144, 767–775
• [18] Taylor H.W., Boyle M., Smith S.C., Bustin S., Williams N.S., Expression of p53 in colorectal cancer and dysplasia complicating ulcerative colitis, British Journal of Surgergery, 1993, 80, 442–444 http://dx.doi.org/10.1002/bjs.1800800411[Crossref]
• [19] Vesna Z., Aleksandar P., Biljana D., et al., Computer-assisted quantitative analysis of Ki67 antigen in dysplasia - associated lesions or masses in ulcerative colitis., Volumen 64, Broj 11, Vojnosanitetski Pregled, Strana 10
• [20] Noffsinger A.E., Miller M.A., Cusi M.V., Fenoglio-Preiser C.M., The pattern of cell proliferation in neoplastic and nonneoplastic lesions of ulcerative colitis. Cancer 1996, 78(11), 2307–23012 http://dx.doi.org/10.1002/(SICI)1097-0142(19961201)78:11<2307::AID-CNCR6>3.0.CO;2-J[Crossref]
• [21] Kullmann F., Fadaie M., Gross V., et al., Expression of proliferating cell nuclear antigen (PCNA) and Ki67 in dysplasia in inflammatory bowel disease, European Journal Gastroenterology Hepatology, 1996, 8(4), 371–379 http://dx.doi.org/10.1097/00042737-199604000-00016[Crossref]
• [22] Keiji M., Hidenobu W., Yoichi A., et al., Ulcerative colitis with overexpression of p53 preceding overt histological abnormalities of the epithelium - Case report, Journal Gastroenterology 1996, 31, 860–867 http://dx.doi.org/10.1007/BF02358616[Crossref]
• [23] Torres M.I., Ríos A., Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy, World J. Gastroenterology 2008, 14(13), 1972–1980 http://dx.doi.org/10.3748/wjg.14.1972[Crossref][WoS]

Identifiers

DOI

10.2478/s11536-009-0085-7